Why patents matter
The principal economic safeguard in our industry is a well-functioning patent system that recognizes our effort and rewards our innovation with appropriate protection. We have blogged quite a bit about...
View ArticleFDA receives critical funding for 2012
AstraZeneca and the Alliance for a Stronger FDA applaud members of the House and Senate for providing FDA with $2.5 billion in funding for 2012—an increase of $50 million. AstraZeneca advocates for a...
View ArticleUS FDA Approves EPANOVA® (omega-3 carboxylic-acids)
By Rod Wooten, Executive Director, AstraZeneca AstraZeneca recently announced that the US Food and Drug Administration (FDA) approved EPANOVA® (omega-3-carboxylic acids) as an adjunct to diet to...
View ArticleUS FDA Approves MOVANTIK™ (naloxegol) Tablets C-II
On September 16, the US Food and Drug Administration approved MOVANTIK™ (naloxegol) tablets C-II as the first once-daily oral peripherally acting mu-opioid receptor antagonist (PAMORA) for the...
View Article